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Protocol
AbstrAct
Introduction Chronic breathlessness is highly prevalent 
and distressing to patients and families. No medication 
is registered for its symptomatic reduction. The strongest 
evidence is for regular, low-dose, extended- release (ER) 
oral morphine. A recent large phase III study suggests the 
subgroup most likely to benefit have chronic obstructive 
pulmonary disease (COPD) and modified Medical Research 
Council breathlessness scores of 3 or 4. This protocol is for 
an adequately powered, parallel-arm, placebo-controlled, 
multisite, factorial, block-randomised study evaluating 
regular ER morphine for chronic breathlessness in people 
with COPD.
Methods and analysis The primary question is what 
effect regular ER morphine has on worst breathlessness, 
measured daily on a 0–10 numerical rating scale. 
Uniquely, the coprimary outcome will use a FitBit to 
measure habitual physical activity. Secondary questions 
include safety and, whether upward titration after initial 
benefit delivers greater net symptom reduction. Substudies 
include longitudinal driving simulation, sleep, caregiver, 
health economic and pharmacogenetic studies. Seventeen 
centres will recruit 171 participants from respiratory and 
palliative care. The study has five phases including three 
randomisation phases to increasing doses of ER morphine. 
All participants will receive placebo or active laxatives as 
appropriate. Appropriate statistical analysis of primary and 
secondary outcomes will be used.
Ethics and dissemination Ethics approval has been 
obtained. Results of the study will be submitted for 
publication in peer-reviewed journals, findings presented 
at relevant conferences and potentially used to inform 
registration of ER morphine for chronic breathlessness.
Trial registration number NCT02720822; Pre-results.
InTroducTIon
There is a growing understanding of the 
complex pathological, neurophysiological, 
emotional and psychospiritual compo-
nents of breathlessness.1 2 The burden of 
this distressing symptom however remains 
Strengths and limitations
 ► This study is adequately powered to provide 
clinically meaningful outcomes.
 ► To optimise the generalisability of the findings, this 
multisite study will capture people from across a 
spectrum of care settings.
 ► This study builds on the experience of several 
double-blind randomised controlled trials 
investigating the role of extended release morphine 
in breathlessness.
 ► This study includes objectives which assess 
changes in habitual function as well as symptom 
control outcomes.
 ► This is a relatively long study for participants from 
palliative care which may potentially influence 
completion rates independently of the intervention.
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devastatingly high for people who experience it and 
their caregivers.3 It is not only a highly feared symptom 
in those approaching end of life4 but unlike many other 
symptoms, breathlessness typically worsens, despite treat-
ment, as death approaches.5 6
Defined as ‘a subjective experience of breathing 
discomfort that consists of qualitatively distinct sensations 
that vary in intensity’7 breathlessness can be described as 
chronic when it persists despite the maximal treatment of 
reversible causes.8–10 Chronic breathlessness is a distinct 
syndrome with implications for patients, caregivers, 
health services, funders and researchers.11 The subjec-
tive experience of chronic breathlessness cannot be 
accurately predicted by diagnosis12 13 or by standard phys-
iological respiratory measures such as spirometry, oxygen 
saturations and respiratory rate.14–16 However, despite the 
lack of investigative predictors, chronic breathlessness 
is severely debilitating both physically and psycholog-
ically.4 13 Over half of people with lung cancer report 
physical limitations due to breathlessness and around a 
quarter describe negative effects on their psychological 
well-being.17 Anxiety can both aggravate chronic breath-
lessness as well as arise from it.18 Depression and overall 
reduced quality of life are also prevalent.19 20 Worsening 
chronic breathlessness is associated with worsening and 
physical and mental components of quality of life at a 
population level.21
Chronic breathlessness has a prevalence of 9%–11% in 
the general community.22 23 As the incidence of chronic 
obstructive pulmonary disease (COPD), heart failure and 
other causes of breathlessness24 continue to rise glob-
ally,25 the problem of chronic breathlessness will continue 
to rise in parallel.
Despite the magnitude of the problem, internation-
ally there is no medication currently registered for the 
symptomatic management of chronic breathlessness. 
Treatment of the underlying cause remains the mainstay 
of therapy10 26 27 although there is increasingly robust 
evidence for various non-pharmacological and pharma-
cological interventions.10 28 Systematic reviews support the 
use of walking aids29 and pulmonary rehabilitation,30 and 
there is randomised trial evidence for multidisciplinary 
breathlessness support services31 and for nurse-led clinic 
support.32 Phase III clinical trial data16 and a meta-anal-
yses33 support the use of oxygen therapy for symptomatic 
relief of chronic breathlessness in people with evidence 
of hypoxaemia. In an adequately powered, randomised 
trial in patients with COPD and chronic breathlessness 
without resting hypoxaemia, oxygen provided no greater 
relief than placebo air.34 Other studies have produced 
conflicting results35 and data in daily life settings are 
limited.36 37
The beneficial clinical role for morphine in chronic 
breathlessness is becoming increasingly established.38 
In vivo laboratory-controlled trials demonstrate opioids 
modulate the work of breathing during exercise and resis-
tive load breathing in both healthy volunteers39 and those 
with COPD.40 41 Clinically, low-dose regular extended 
release (ER) morphine reduces the intensity of chronic 
breathlessness without compromising gas exchange in 
people with moderate to severe COPD.9 42 These data 
are further validated in two recent systematic reviews 
and meta-analyses specifically exploring opioids for the 
relief of breathlessness in COPD.43 44 Although systemic 
morphine improves breathlessness in COPD, there is 
no evidence to date that it improves exercise capacity 
measured by 6 min walk test or duration on treadmill.43
Pharmacovigilance data show no evidence of tachyphy-
laxis or tolerance during up to 22 months of follow-up 
of people using ER morphine for chronic breathless-
ness with dose titrated to benefit.45 The patients’ and 
caregivers’ experience of use of morphine for chronic 
breathlessness is also positive with minimal adverse effects 
reported when used specifically at low doses for chronic 
breathlessness46–48 although the benefits can be easily 
negated by any side effects from the ER morphine.49 In 
broader post-marketing studies of opioid use in people 
with COPD where clinical indications are predominantly 
for musculoskeletal pain, findings in two separate popula-
tion-based studies are conflicting.48 50 Additionally, there 
is some evidence demonstrating increased sleep quality 
when using opioids for breathlessness.51
Despite recent recommendations in several 
international clinical guidelines,15 26 27 including recom-
mendations in the most recent Global Strategy for the 
Diagnosis, Management, and Prevention of Chronic 
Obstructive Lung Disease 2017 and its associated peer-re-
viewed executive summary which state that ‘palliation 
efforts should be focused on the relief of dyspnoea’52 
and that opiates can relieve dyspnoea,53 some physi-
cians remain reluctant to prescribe morphine and other 
opioids for breathlessness.46 54 A recent cohort study has 
also questioned the safety of initiating opioid use in older 
adults but this was based on dispensing data rather than 
observed adverse effects55 and from other population data 
of opioid prescribing, it is highly unlikely that very many 
of these prescriptions were for chronic breathlessness.56 
Opioid-related adverse effects (transient drowsiness, 
nausea, itch, constipation, anticholinergic effects and 
physical tolerance) are well documented; however, 
prospective data to date have failed to demonstrate any 
episodes of respiratory depression or morphine-related 
hospitalisations when morphine is used at low dose and 
in steady state conditions.43 45 Additionally, all relevant 
systematic reviews comment on the low incidence of 
morphine-related serious adverse effects.38 43
ER morphine preparations may be useful in improving 
safety and reducing the potential for side effects when 
used for chronic breathlessness when compared with 
immediate release oral morphine solution. Although data 
are extrapolated from studies investigating pain manage-
ment, pharmacokinetic data suggest there is less variability 
between maximum and minimum dose concentrations 
with ER opioid preparations.57 Adherence is improved 
with the use of once daily preparations,58 an approach 
which is also preferred by patients.59 Further, randomised 
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double-blind studies show more rapid pain control and 
fewer side effects when ER opioid preparations are used 
compared with immediate release preparations even 
when initiating opioids for pain.60 61
This paper presents the protocol for an Australian 
national multisite study that aims to improve the current 
evidence base for the role of ER morphine in the manage-
ment of chronic breathlessness. Parts of this study design 
are exploratory, parts will definitively answer new ques-
tions and several exploratory substudies are included. 
A list of the key questions that this study protocol will 
address are summarised in box 1 with features unique 
to this study highlighted. This paper complies with the 
Standard Protocol Items: Recommendations for Interven-
tional Trials recommendations for protocol reporting62 63 
and the study will report against Consolidated Standards 
of Reporting Trials guidelines.64 65
MeThods and analysIs
study design
The Breathlessness, Exertion And Morphine Sulfate 
(BEAMS) study is a phase III multisite, double-blind, 
parallel-arm, block-randomised, factorial, placebo-con-
trolled, dose increment study of ER morphine for chronic 
breathlessness in participants with COPD. The study has 
five stages which will incorporate three randomisations 
for each participant to titrate dose of ER morphine. The 
study protocol also incorporates nine substudies. Partic-
ipants may elect to participate in one or more of these 
substudies.
recruiting centres
The BEAMS study is coordinated by the Australian 
national Palliative Care Clinical Studies Collaborative 
(PaCCSC) and is sponsored by Flinders University, 
Adelaide, Australia. Box 2 details a list of sites involved in 
study participant recruitment, noting additional sites may 
become involved as study recruitment progresses.
study objectives
The BEAMS study has two coprimary objectives: to 
compare the effect of ER morphine at two different doses 
and placebo on mean worst breathlessness on the last 
3 days of 1 week of treatment and to compare the mean 
change in number of steps taken by participants per day 
in the last 3 days of week one compared with baseline in 
both ER morphine and placebo arms as measured by a 
FitBit Charge HR (FitBit, USA).
The secondary objectives of the study are to determine:
 ► The safety of ER morphine, including the effect of 
upward dose titration in a participant population of 
people with COPD with chronic breathlessness;
 ► The additional symptomatic benefit of increasing 
dose in participants whose breathlessness is benefited 
by low-dose ER morphine;
 ► Over what period of time does benefit continue to 
increase if a beneficial dose level is achieved66;
 ► The percentage of participants that derive benefit at 
each dose above placebo;
 ► Any existence of end-of-dose failure;
 ► If response, benefit and side effects to ER morphine 
can be predicted from collected baseline demographic 
data;
 ► The impact on general health status and quality of life 
of both participant and caregiver;
Box 1 Key questions addressed by this study protocol
Key questions:
 ► In steady state, what effect does extended release (ER) morphine 
have on worst breathlessness in patients with chronic obstructive 
pulmonary disease (COPD) and chronic breathlessness?
 ► In the same patients, what effect does ER morphine have on physical 
activity assessed by accelerometer steps per day?*
 ► If there is benefit, what is the optimal dose and is there a dose-
related response to upward titration, especially after initial 
symptomatic benefit?*
 ► What is the net effect of morphine for up to 6 months in its effect on 
chronic breathlessness and harms associated with its use?*
 ► What is the harm profile of ER morphine for chronic breathlessness 
over time?
 ► Does low-dose ER morphine used for chronic breathlessness impact 
quality of life, driving simulation performance and sleep quality?
 ► Through pharmacokinetic and genetic analysis, can we begin 
to identify which patients may benefit from, have no effect or 
experience harm from ER morphine for chronic breathlessness?*
 ► What is the economic impact of ER morphine on this population for 
this indication?
*Not studied before in this population for this indication.
Box 2 List of recruiting centres
New South Wales
Sacred Heart Health Service, Darlinghurst
Calvary Mater, Newcastle
Calvary Healthcare, Kogarah
Liverpool Hospital, Liverpool
Concord Repatriation Hospital, Concord
Greenwich Hospital, Greenwich
Queensland
Mater Health Service, Brisbane
The Prince Charles Hospital, Chermside
Nambour Hospital, Nambour
St Vincents Private Hospital, Brisbane
South Australia
Southern Adelaide Palliative Services, Daw Park
Repatriation General Hospital, Daw Park
Victoria
Barwon Health, Geelong
Royal Melbourne Hospital, Melbourne
St Vincent’s Hospital, Melbourne
Austin Hospital, Heidelberg
Western Australia
Sir Charles Gairdner Hospital, Nedlands
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 ► Differences in activities of daily living (ADLs) between 
those treated with ER morphine and placebo;
 ► The effect of ER morphine and placebo on anxiety 
and depression;
 ► The longer term benefits and side effects of ER 
morphine;
 ► Blinded patient preference of intervention and dose;
 ► If participants experience opioid withdrawal as study 
medicines cease.
The aims of the substudies are detailed in the relevant 
section below.
study population
The study population for BEAMS is people with COPD 
and chronic breathlessness graded as modified Medical 
Research Council grade 3 or 4 and whose worst breath-
lessness intensity in the 24 hours prior to recruitment is 
greater or equal to 3/10 on a 0–10 numerical rating scale 
(NRS). In addition to being 18 years of age or older and 
able to complete the assessments in English, the study’s 
inclusion criteria are:
1. Physician-diagnosed COPD with spirometry 
confirmation, defined as a postbronchodilator forced 
expiratory volume in 1 s over forced expiratory volume 
of <0.7 consistent with Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) criteria67;
2. Clinician confirmed optimisation of COPD treatment;
3. Stable medication for management of COPD-
related breathlessness for 1 week, except ‘as needed’ 
medications;
4. Assessed as competent to be able to provide informed 
consent with a mental state examination as defined 
by the St Louis University Mental State Examination68 
23/30 and at the discretion of the principal 
investigator.
A number of exclusion criteria will be applied 
detailed in box 3.
recruitment and consent
The BEAMS study will be promoted to patients with 
COPD that interferes with ADLs through LungNet (Lung 
Foundation Australia) and the Primary Health Networks 
in each recruitment catchment area. Potentially eligible 
participants will be identified and approached by both 
primary and secondary care clinicians at participating 
sites across Australia who will then refer them to the 
research team. Research team attendance at relevant 
clinics and study advertisements will help to remind clin-
ical staff of study recruitment and encourage patients to 
self-refer. Permission will be sought from consultants in 
charge of the care of potential participants for research 
staff to approach them directly. Case identification in 
both inpatient units and outpatient clinics will also occur 
following case-note review.
No participant will be recruited without full, written 
informed consent being first obtained. A process of 
information exchange between potential participants 
and research staff including the use of participant infor-
mation sheets and open discussion will occur to ensure 
full disclosure and to comply with Good Clinical Practice 
(GCP) guidelines.69
Eligibility to participate will be determined initially by 
the research team study nurse and site investigators at 
each site involved. They will be responsible for comple-
tion of the medical assessment and to check eligibility 
criteria. Eligibility data will be entered on a secure online 
database and eligibility will be monitored centrally before 
confirmation of study participation and baseline assess-
ments made.
randomisation
At each participating site, consenting participants will 
be sequentially allocated a unique identifying number 
(ID number) according to PaCCSC standard operating 
procedures. Randomisation requests will take the form 
of receipt of a prescription for study medicines by site 
pharmacists. Randomisation will occur through the devel-
opment of randomisation tables using random number 
tables generated by an independent provider. Site phar-
macists will receive the next randomisation number 
available through telephone contact with the central 
registry.
As noted, the study has five stages (0–4: table 1). The first 
randomisation (stage 1) will occur by a block randomisa-
tion schedule held by the independent provider’s central 
registry in a 1:1:1 ratio to either 8 mg ER morphine, 16 mg 
ER morphine or placebo (table 1). Block randomisation 
will ensure relatively even allocation to each of the three 
arms at each site. Similar block randomisation will occur 
at second (stage 2) and third randomisations (stage 3) in 
a ratio of 1:1 to either an additional 8 mg ER morphine or 
placebo at each stage progression.
By the end of the third randomisation, participants will 
have a 1/12 chance of being on placebo, a 3/12 chance 
of being on 8 mg ER morphine, 4/12 chance of 16 mg 
ER morphine, 3/12 chance of 24 mg ER morphine and 
1/12 chance of 32 mg ER morphine, thus allowing assess-
ment of potential benefit of low-dose ER morphine and 
the effects of incremental dose escalation up to 32 mg ER 
morphine for chronic breathlessness.
Randomisation number and allocation will be provided 
to the site pharmacist verbally and confirmed by email. 
Participant ID number, randomisation allocation code, 
date of request, preparation and dispensing data will be 
recorded in a log maintained by the site pharmacist. All 
research staff, treating clinicians and patients will remain 
blinded to the treatment allocation. Unblinding will only 
occur in emergency situations following consultation 
with the principal investigator and at the conclusion of 
collecting the last data point for the last participant in the 
entire study.
Concomitant interventions
All study participants will receive written advice 
detailing standard therapeutic strategies for managing 
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breathlessness. They will also be provided with a 
battery-operated, handheld fan70 and instructions for use 
throughout the study period as standard breathlessness 
management strategies. All other medications and ther-
apies will continue throughout the study period for each 
participant.
Blinding
All medicines used in the study will appear identical to 
ensure true blinding to the intervention. ER morphine 
capsules will contain either 8 mg or 16 mg of a currently 
licensed once daily ER morphine preparation within 
a gelatine capsule to be taken orally. Placebo capsules 
contain appropriately dyed sugar seed cores within an 
identical gelatine capsule. The creation of identical 
appearing capsules with differing contents will also ensure 
that all study participants take two capsules of study drug 
each morning orally for the entire duration of the study. 
The capsule contents will change according to the arm 
and randomisation stage. In addition, participants will 
take two capsules containing either active laxative (docu-
sate 50 mg with sennosides 8 mg) or identical appearing 
placebo each morning. The participant will swallow each 
capsule whole.
All study medicines will be supplied as a once-daily dose 
in a weekly blister (Webster) pack, blinded and dispensed 
by site pharmacists. Dispensing pharmacists will log the 
participant name and ID number and the pack dispensed 
to that participant. Storage, delivery, dispensing and 
destruction of opioid medications will adhere to federal 
and local regulations. Empty packs will be collected for 
reconciliation.
Participants will be reviewed at baseline and a FitBit 
Charge HR will be fitted to record accelerometer data 
including steps per day, activity and basic sleep data in 
weeks one and three of the study.
data collection and outcome measures
Table 2 provides an overview of the data collection tools 
used in this study and table 3 describes the tools and data 
collected at each study time point.
The first coprimary objective will be assessed by the mean 
change in worst breathlessness intensity measured each 
morning on the last three mornings of week 1 compared 
between arms and adjusted for rates measured at baseline. 
Both the intensity and the unpleasantness1 71 of breath-
lessness will be rated by patients each morning based on 
breathlessness in the preceding 24 hours on an 11-point 
Table 1 The five stages of the BEAMS study
Time period Detail
Stage 0 2 days Baseline assessments:
 ►Diary entries for 2 days to provide stable baseline data and to become accustomed to data 
collection tools
 ►Baseline demographic data, physical assessment, research team mediated questionnaires, 
assessments and testing
 ►Fitbit assessment of baseline function
 ►Provided with handheld fan and practical advice on managing breathlessness
Stage 1 1 week First randomisation:
 ►Randomisation 1:1:1 to receive either placebo or 8 mg ER morphine or 16 mg ER morphine
 ►Participants receiving ER morphine will also receive docusate with senna. Placebo arm will 
receive identical placebo laxative
 ►Fitbit assessment of function
Stage 2 1 week Second randomisation:
 ►While continuing in arm assigned at first randomisation, add second randomised treatment.
 ►1:1 randomisation to the addition of either placebo or 8 mg ER morphine
 ►Blinded docusate with senna will replace laxative placebo for those newly randomised to receive 
ER morphine.
Stage 3 1 week Third randomisation:
 ►While continuing in arms assigned at first and second randomisation, add third randomised 
treatment.
 ►1:1 randomisation to addition of either placebo or 8 mg ER morphine
 ►Blinded docusate with senna will replace laxative placebo for those newly randomised to receive 
ER morphine.
 ►Fitbit assessment of function
Stage 4 Up to 
6 months
Optional extension study:
 ►Participant may continue blinded treatment for up to 6 months on the final dose to which they 
were titrated.
 ►Assessments establishing long-term net effects of study medication
BEAMS, Breathlessness, Exertion And Morphine Sulfate; ER, extended release.
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(0–10) NRS with 0 representing ‘no breathlessness’ or 
‘breathing is not unpleasant’ and 10 ‘worst possible breath-
lessness’ or ‘most unpleasant breathlessness possible’. 
Scores will be recorded in a patient diary. Primary compar-
isons at the completion of stage 1 will be between 8 mg 
ER morphine and placebo and 16 mg ER morphine and 
placebo. A difference of one point on NRS will be consid-
ered a clinically meaningful difference; consistent with 
consensus statements72 and empirical studies.73
The choice of worst breathlessness is based on data from 
a recent large randomised controlled trial comparing 
regular, low-dose, ER morphine with placebo for chronic 
breathlessness. The most responsive measure from 
unpleasantness and intensity (now, average, best and 
worst) was worst breathlessness in the previous 24 hours.74 
This directly reflects previous work that compared the 
performance of NRS measures of breathlessness with a 
modified Borg scale in 1048 participants.75 Worst breath-
lessness has the widest distribution of responses, whereas 
average breathlessness appeared to have a ceiling effect 
and breathlessness now had a much smaller range of 
responses.
There are potential parallels with pain when consid-
ering average, worst and current pain in people treated 
with radiotherapy for painful bony metastases: worst pain 
had the strongest correlation with functional interference 
at baseline and larger decreases in functional interfer-
ence scores as pain was relieved.76 Of all the measures in 
the Brief Pain Inventory, ‘pain at its worst in the previous 
24 hours’ satisfied more of the key Food and Drug Admin-
istration recommendations for patient reported measures 
than any other.77
The second coprimary objective will be assessed by 
comparison of number of steps taken per day as recoded 
using a Fitbit Charge HR on the last 3 days of stage 1 and 
with baseline. Comparisons will be made between 8 mg 
ER morphine and placebo and 16 mg ER morphine and 
placebo. A secondary endpoint will also occur at the 
end of stage 3. A clinically meaningful difference has 
been calculated to be 940 steps per day, which is one 
half of an SD in people with GOLD grade IV COPD67 in 
previous studies comparing exercise training in partic-
ipants with varying levels of COPD.78 79 Accelerometers 
measure habitual physical activity with a 3–5 day period of 
recording considered sufficient to have stable data.80 By 
contrast, a 6 min walk test measures functional exercise 
capacity,81 with the measures complementing each other. 
It is more likely that any improvement in symptoms will be 
reflected in great mobility across each day, rather than in 
functional exercise capacity, especially given the evidence 
to date on the effect of opioids on exercise capacity.43 82
Secondary outcomes will be assessed by completion of a 
number of validated participant and research team-medi-
ated measures at various time points throughout the study 
period (table 2). These measures will provide quantita-
tive and qualitative assessments of participants’ symptom 
severity and ensure measurement of quality of life (QoL) 
for both participants and caregivers in line with the 
Australian national Palliative Care Strategy’s aims.83
The participant diary will remain the most important 
source of data collection. Diary completion by participants 
throughout stages 1, 2 and 3 will document daily NRS 
recording of both the intensity (worst, now, average) and 
unpleasantness of breathlessness. It will also allow docu-
mentation of Likert-scale grading of sleep quality, clarity 
of thought, daytime drowsiness, constipation, nausea, 
vomiting, itch, difficulty with micturition and any other 
patient-identified symptoms. During stage 4, participants 
will complete diary entries for a 24-hour period each week 
and will have additional questions on additional adverse 
events such as falls and Australia-modified Karnofsky 
Performance Status (AKPS). Particular emphasis will also 
be placed on data collection of health service utilisation 
rates and quality of life data to inform the economic anal-
ysis substudy. Participants will be contacted regularly by 
telephone during each week of intervention to ensure 
safety and compliance.
Additional information at the end of stage 3 will be 
recorded including blinded participant preference for 
treatment at study conclusion, medication compliance 
and differential rates of withdrawal from the study. All 
participants will be asked to complete the Subjective 
Opioid Withdrawal Scale84 assessment for three consec-
utive days after completion or withdrawal from the study.
Blood sampling will occur at baseline to record haemo-
globin level, hepatic function and to calculate creatinine 
clearance unless a sample is available from the preceding 
4 weeks without any change in clinical condition. This 
will ensure absence of reversible causes of breathlessness 
such as anaemia and organ dysfunction that may impact 
Box 3 Exclusion criteria
 ► Opioid use for breathlessness in the previous 7 days
 ► Regular opioid use for any other reason (including codeine 
preparations) at or above 8 mg oral morphine equivalent per day in 
the previous 7 days
 ► History of adverse reactions to any study medications or placebo 
constituents
 ► An Australian-modified Karnofsky Performance Score108 of less than 
50 at baseline assessment
 ► Respiratory or cardiac event in the previous 7 days excluding 
upper respiratory tract infections. Acute illness should be deemed 
as resolved prior to baseline assessment by participant’s treating 
physician
 ► A resting respiratory rate of<8 breaths per minute
 ► Documented central hypoventilation syndrome
 ► Current or recent history of abuse of alcohol or substance misuse
 ► Uncontrolled nausea, vomiting or evidence of gastrointestinal tract 
obstruction
 ► Renal dysfunction with calculated creatinine clearance of less than 
20 mL/min
 ► Evidence of severe hepatic impairment as defined as greater than 
four times normal transaminase levels or bilirubin level (excluding 
Gilbert’s syndrome)
 ► Current pregnancy or breastfeeding
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Table 2 Overview of the questionnaires and scales used in the BEAMS study
Breathlessness 
assessments
Intensity of worst breathlessness over the previous 24 hours
 ►  NRS
 ►0–10 (11-point) scale
 ►0 = ‘no breathlessness’ to 10 = ‘worst possible breathlessness’
Unpleasantness of worst breathlessness over the previous 24 hours
 ►  NRS
 ►0–10 (11-point) scale
 ►0 = ‘breathing is not unpleasant’ to 10 = ‘most unpleasant breathlessness possible’
mMRC109 110
 ►  Five-point (0–4) categorical breathlessness scale
 ►  Descriptive measure of functional impairment due to breathlessness; lower scores indicate less 
breathlessness.
CRQ-DS111 112
 ►  Total of 20 questions covering social and emotional symptoms and perceptions of breathlessness in 
relation to five activities over the preceding 2 weeks
 ►  Higher scores indicate better respiratory function.
CRQ-M113
 ►  Assessment of perceived change in patient mastery over their breathlessness
 ►  Higher scores indicate better mastery.
Baseline 
assessments
CCMI114
 ►  Severity and number of comorbid conditions incorporated into a single score.
 ►Score will be unweighted and not include participants life-limiting illness.
 ►  Independent predictor of long-term survival115
SLUMS68
 ►  11-item questionnaire scored out of 30; testing memory, orientation, attention and executive functions
 ►  Score adjusted for school education.
ESAS116
 ►  Rating of severity of coexisting symptoms on a numeric rating scale from 0 to 10
 ►  Sum of scores is termed symptom distress score. Higher scores equate higher levels of distress.
Performance 
and activity 
assessors
Activity monitoring
 ►  Daily step count measured by Fitbit Charge HR wearable step count technology device
 ►  Provides data and insight into overall physical activity including steps per day, sleep minutes and sleep 
activity, activity and sedentary levels and total energy expenditure117
 ►  Motion sensors provide an objective, reliable, valid and responsive measure118 119
AKPS108
 ►  Validated variant of Karnofsky Performance Status
 ►  Scored 0–100 in increments of 10 assigned to participants based on ability to perform activities of daily 
living; higher scores imply better level of function.
Barthel Index (clinician rated)120–122
 ►  Assess impairment of ADLs through assessment of 10 variables
 ►  Higher scores indicate associated with increased independence with ADLs.
Mood HADS123
 ►  14-item questionnaire consisting of two seven-item subscales looking at depression and anxiety, 
respectively
 ►  Higher scores are associated with greater morbidity.
Continued
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on study medication pharmacology. This sample will also 
be used for the pharmacogenetic study. Bloods in steady 
state will also be taken at the end of weeks 1 and 3 to 
understand any relationship between blood levels and 
symptomatic response. Baseline testosterone levels will 
be measured for all participants at baseline and again 
at 6 months for those who enter the testosterone level 
substudy.
To assess for the risk of opioid-induced respiratory 
failure from low-dose ER morphine, end-tidal carbon 
dioxide (CO2) and pulse oximetry will be recorded using 
a portable unit at baseline and at the three, weekly rando-
misation stages. Recent spirometry from any source will 
be recorded to confirm the COPD diagnosis.
In addition to age and gender, demographic data 
including domestic situation, educational and marital 
status, availability of primary caregiver, ethnicity and 
Aboriginal or Torres Strait Islander status will be recorded. 
Smoking history and use of long-term oxygen therapy 
will also be recorded at baseline. A full baseline physical 
examination will also be conducted. First randomised 
treatment will commence the day following completion 
of the baseline 2-day assessment period.
Participant safety will remain of paramount importance 
throughout the study period. Rescue medication will 
therefore be available for participants for treatment of 
common opioid side effects including nausea and consti-
pation. Opioid toxicity is defined by physician assessment 
of respiratory depression (≤10 breaths per minute), 
drowsiness, myoclonus, myosis or National Cancer Insti-
tute Common Terminology Criteria for Adverse Events 
version 4 (NCI CTCAEv4)85 grade ≥3 for cognitive 
Quality of life 
assessments
Quality of Life EQ-5D-5L124
 ►  Standardised instrument for use as a measure of health outcome in both clinical and economic evaluation 
of healthcare
 ►  Five descriptive questions rated on a 5-point Likert scale and a single VAS rating overall health.
CAT125
 ►  Validated measure of heath-status in COPD and is responsive to quality of life changes after an 
exacerbation and pulmonary rehabilitation.
 ►  Eight questions specific to COPD-related symptoms each rated on a 6-point scale.
GIC126
 ►  Seven-point scale regarding participant perception of change since study commencement; graded from 
‘very much worse’ to ‘very much improved’
 ►  Adapted for measurement of breathlessness from original127
 ►  Higher scores imply better global quality of life.
Sleep 
assessments
ESS128
 ►  Validated tool for characterising daytime sleepiness
 ►  Eight questions rated on a four-point scale
LSEQ129
 ►  Validated tool for measuring changes in sleep such as going to sleep, perceived quality of sleep and 
morning alertness
 ►  Ten questions self-rated on 0–100 millimetre (mm) line
KSS130 131
 ►  Validated single question on a nine-point scale evaluating subjective sleepiness
 ►  Higher scores indicate higher perceived sleepiness at the time of scoring.
Caregiver Zarit Burden Interview132
 ►  Caregiver well-being assessment 12-item short form questionnaire133
 ►  Commonly used questionnaire assessing level of subjective caregiver burden rated on a five-point Likert 
scale
Adverse effects SOWS84
 ►  16-point questionnaire rating presence of signs and symptoms of opioid withdrawal on a five-point Likert 
scale
 ►  Higher scores indicate increasing severity of opioid withdrawal.
ADLs, activities of daily living; AKPS, Australian-modified Karnofsky Performance Status; BEAMS, Breathlessness, Exertion And Morphine 
Sulfate; CCMI, Charlson Co-Morbidity Index; CAT, COPD Assessment Test; COPD, chronic obstructive pulmonary disease; CRQ-DS, Chronic 
Respiratory Questionnaire—Dyspnoea Subscale; CRQ-M, Chronic Respiratory Questionnaire—Mastery Subscale; ESAS, Edmonton Symptom 
Assessment System; ESS, Epworth Sleepiness Scale; GIC, Global Impression of Change; EQ-5D-5L, Five-Level EuroQol five dimensions 
questionnaire; HADS, Hospital Anxiety and Depression Scale; KSS, Karolinska Sleepiness Scale; LSEQ, Leeds Sleep Questionnaire; mMRC, 
modified Medical Research Council; NRS, Numerical Rating Scale; SOWS, Subjective Opioid Withdrawal Scale; SLUMS, St Louis University 
Mental Status Examination; VAS, Visual Analogue Scale. 
Table 2 Continued 
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impairment, confusion or somnolence. Signs suggestive 
of opioid toxicity will result in urgent physician assess-
ment, investigation of contributing factors and treated 
with either opioid dose reduction or naloxone according 
to the severity of the toxicity and degree of respiratory 
compromise.
Reasons for cessation of study drug or withdrawal from 
the study include treatment failure as defined by unac-
ceptable side effects of NCI CTCAEv4 grade 3 that do 
not settle with symptomatic intervention or grade 4 or 5 
harms. Participants may also be withdrawn if treatment 
is deemed ineffective by treating clinician, increasing 
breathlessness scores despite study treatment or with-
drawal of participant consent.
substudies
As previously mentioned, the BEAMS study protocol also 
incorporates nine substudies (table 4). Participants may 
elect to participate in one or more of these to enrich the 
study data collection. The timing of the substudy assess-
ments are also detailed in table 3.
Morphine/metabolite levels substudy
Participants who consent to be included in this substudy 
will have one blood taken at baseline and then trough 
levels on 1 day at the end of the first and third weeks of 
the study. Levels for morphine and its active metabolites 
(morphine, morphine-3-glucuronid and morphine-6-glu-
curonide) will be analysed and response to chronic 
breathlessness parameters explored. This will be particu-
larly important in terms of symptomatic response to the 
two morphine dose levels for the primary outcome and to 
adverse effects for the secondary outcomes.
Pharmacogenetic substudy
Changes in the binding capacity of the mu-opioid 
receptor (MOR) or in the pathways of morphine metab-
olism are thought to account for observed variation in 
the responses to opioids.86 Although such variations are 
being increasingly described in the context of response 
of pain to opioids, they have yet to be tested prospectively 
in the response of breathlessness.87 Participants who 
consent to inclusion in the pharmacogenetic substudy 
will have a single baseline blood test taken for laboratory 
analysis. Blood samples will be assessed for the presence 
of single-nucleotide polymorphisms (SNPs) known to 
modify MOR activity including A118G, UGT2B7*2 and 
828 polymorphisms. P-glycoprotein (ABCB1 5SNPs in a 
haplotype block) and interleukins (IL), IL-1B and IL-6, 
and other innate immune pathway gene variants as well 
as variants associated with opioid responses (such as cate-
chol-O-methyltransferase) will also be measured given 
their association with morphine requirements in acute 
pain.86 Previous work by the investigators has shown 
that different doses of morphine may be required by 
different people to manage chronic breathlessness.6 It 
has also been shown in a hypothesis generating study of 
112 SNPs from 25 genes that people on morphine with 
5-hydroxytryptamine type 3B gene rs7103572 SNP were 
three times more likely to have more intense breathless-
ness while on morphine88
Baseline blood samples will be stored frozen then trans-
ferred to Adelaide for genetic analysis. Genetic analysis 
will be correlated with responses to randomised study 
interventions.
Sleep substudy
Thirty participants will be invited to undertake a home 
sleep study at baseline and during the last 3 days of stage 3 
(post third randomisation in steady state). This will allow 
data collection on overnight measures of breathing and 
oxygenation to compare with more subjective sleep assess-
ments and questionnaires. Following a demonstration 
of use, participants will be asked to wear an ApneaLink 
Plus (ResMed, San Diego, California, USA) home sleep 
diagnostic device for one night at baseline and one night 
during stage 3. The device will measure oximetry, nasal 
airflow pressures and chest movements and has a high 
sensitivity and specificity in defining breathing distur-
bances.89 90
Up to 20 participants will also be invited to undergo two 
inlaboratory polysomnography overnight sleep studies to 
objectively quantify sleep quality according to the GOLD 
standard.91 92
Driving substudy
A driving simulation task will be performed in 30 
consenting participants to assess data on steering, crash 
incidence and reaction time using the AusEd (Wool-
cock Institute for Medical Research, Sydney, Australia) 
computer-based driving simulation programme.93 Partic-
ipants will be asked to complete a baseline assessment 
questionnaire to capture driving history as well as a base-
line simulation. Results will be compared with driving 
simulation assessments performed at day 2 and day 7 after 
the first randomisation and will be compared with data 
obtained on sleep quality94 and study medicines.
Patients’ and caregivers’ qualitative substudy
Previous qualitative studies have examined the experi-
ences of patients and their caregivers living with chronic 
breathlessness as a result of COPD and their attitudes 
to use of opioids.46 95 Patients and caregivers will be 
approached at baseline to consent to be included in this 
substudy. They will be asked to participate in an individual 
qualitative interview exploring perceptions surrounding 
these issues in greater detail. As this substudy will also 
recruit participants who are unable to participate in 
BEAMS, it may capture data from people not willing to 
take morphine for symptomatic reduction of chronic 
breathlessness.
Economic evaluation substudy
The main objective of this substudy is to determine the 
incremental costs and consequences of ER morphine use 
for symptomatic management of chronic breathlessness 
in people with COPD. The primary outcome measure 
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Table 4 Brief description of the substudies included in the BEAMS study protocol
Substudy title Participants Substudy details
Morphine/morphine 
metabolite sub-study
55  ►  Aim: to determine the relationship between the steady-state plasma 
concentrations of M3G and M6G along with the effects of renal function with 
change in breathlessness intensity
 ►  Blood samples collected at baseline and steady state at trough levels end of 
week 1 and week 3
Pharmacogenetic 
substudy
All consenting  ►  Aim: identification and assessment of genetic variations in opioid receptor, 
neuronal, immune, metabolic or signalling pathways that may influence 
clinical responsiveness to ER morphine for symptomatic treatment of chronic 
breathlessness
 ►  Blood sample collection at baseline
Sleep substudy 30
20
 ►  Aim: to investigate the effect that study interventions have on sleep quality
 ►  Data obtained from Fitbit Charge HR for all participants
 ►  Thirty participants recruited to non-invasive, home-based sleep studies at 
baseline and at the end of stage 3
 ►  Up to 20 participants from two centres (Sydney and Adelaide) will participate in 
two formal overnight laboratory sleep studies at baseline and at the end of stage 
3.
Driving substudy 20  ►  Aim: assess effects of introducing and steady-state ER morphine use on driving 
simulator performance in subgroup of participants
 ►  Short questionnaire to assess driving history
 ►  Participants from two centres (Sydney and Adelaide) will complete three 30 min 
office-based driving simulations. One at baseline, one on day 2 and again on 
day 7 of stage 1.
Caregiver well-being 
substudy
All consenting  ►  Aim: to compare the impact on caregiver well-being between study 
interventions when compared with baseline
 ►  Caregivers asked to provide basic demographic data and complete the Zarit 
burden interview 12-item short-form questionnaire133
 ►  Assess level of subjective burden at baseline and the end of stages 1, 2, 3 and 
4 (or study withdrawal)
Patient and caregiver 
qualitative substudy
All consenting  ►  Aim: to understand the experience of living with chronic breathlessness and the 
attitudes towards ER morphine use for its symptomatic treatment
 ►  Limited to participants from Adelaide
 ►  Separate patient and caregiver qualitative interviews
 ►  People who decline to participate in the BEAMS study but who fulfil the 
inclusion criteria will also be offered participation in this substudy.
Economic analysis 
substudy
All consenting  ►  Aim: to compare within trial incremental costs and cost effectiveness of regular 
low-dose ER morphine using prospectively collected data
 ►  Data collected will include hospitalisations, presentations to emergency 
departments, use of primary care, allied health practitioners and palliative care 
services throughout the study and for 4 weeks after last study medication is 
given.
Testosterone level 
substudy
All consenting 
from stage 4
 ►  Aim: to further evaluate changes in total testosterone levels given concerns in 
previous studies that suggest morphine may reduce testosterone levels134 135
 ►  Prospectively obtained blood samples at baseline and on completion of stage 4
Cortisol substudy All consenting 
(who have 
not been on 
glucocorticoids 
in the preceding 
4 weeks)
 ►  Aim: to understand if hypothalamic–pituitary–adrenal axis dysregulation of 
chronic disease is influenced by reduction in chronic breathlessness as a 
stressor, with some return of normal diurnal variation.
 ►  Saliva tests three times each of 8 days across the study.
BEAMS, Breathlessness, Exertion And Morphine Sulfate; ER, extended release; M3G, morphine, morphine-3-glucuronid; M6G, morphine-6-
glucuronide.
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of this study will be cost per responder as recommended 
by the Pharmaceutical Benefits Advisory Committee.96 
Data will be collected from first randomisation to 28 days 
post treatment (or death, if shorter) for each patient 
regarding:
 ► Efficacy of study medicines;
 ► Days of survival;
 ► Days of survival with breathlessness rated as mild or 
absent;
 ► Five-Level EuroQol Five Dimensions Questionnaire 
scores of health-related quality of life;
 ► Number of inpatient admissions and presentations to 
emergency departments;
 ► Outpatient, general practitioner, palliative care team 
visits;
 ► Concomitant medicines.
These data will allow within-trial modelling using 
bootstrapping methods of replicates for costs and conse-
quences of alternative strategies, allowing for covariance 
between costs and effects.97 Incremental net monetary 
benefit98 and cost-effectiveness acceptability curves99 
will be estimated at potential threshold values for an 
additional responder. Quality-adjusted life years will be 
estimated if differences in QoL assessments are found 
between active treatment and placebo.
Testosterone substudy
All participants who consent to be included in the optional 
stage 4 study extension will be approached to participate 
in an additional substudy looking at prospective analysis 
of testosterone levels in patients on morphine. Partic-
ipants who consent will have a blood sample taken at 
baseline for total testosterone levels and again at the end 
of the 6-month stage 4 extension.
Cortisol substudy
Evidence suggests that patients with moderate-to-severe 
breathlessness have dysregulation of the normal circadian 
rhythm of cortisol production characterised by flatter 
mean diurnal cortisol slopes compared with people with 
mild or no breathlessness.100 Importantly, flatter cortisol 
slopes have been shown to predict a decrease in function, 
worse physical performance and mortality in patients 
with chronic conditions.101–103 Morphine has been shown 
to relieve the sensation of breathlessness in people with 
chronic diseases which may decrease physiological stress 
and thus modify the hypothalamic–pituitary–adrenal 
axis’ response over time.
All willing participants will be included in this substudy 
unless they were treated with systemic corticosteroids in 
the previous 4 weeks or suffer from insulin-dependent 
diabetes. The salivary cortisol profile will be analysed 
with respect to two summary parameters recommended 
for cortisol assessment in randomised controlled 
trials100:
1. diurnal cortisol slope
2. cortisol area under the curve.
Each participant will be required to collect three saliva 
samples per day across 8 days: 2 days at baseline, 2 days in 
stage 1, 2 days in stage 3 and 2 days at the end of the third 
month of the extension phase. Samples will be collected at 
3, 6 and 12 hours after awakening using Salivette Cortisol 
devices (SARSTEDT, Australia). Within and between-
group changes will be analysed from baseline through 
the follow-up period. Multilevel modelling will be used to 
conduct the statistical analysis.
sample size calculation
All calculations assume a type I family-wise error rate 
(FWER) of 5% and type II error rate of 20% (power of 
80%). The primary analysis comprises two comparisons 
made at the end of stage 1 (placebo compared with 8 mg 
ER morphine and placebo compared with 16 mg ER 
morphine), each assessed at alpha=0.025 (two sided) to 
protect the overall type 1 error rate. Using variance–cova-
riance matrices from previous studies by PaCCSC that 
have investigated worst breathlessness in the previous 
24 hours,104 it is calculated that a total sample size of 
171 subjects will be required to provide over 80% power 
and allow for a 20% rate of attrition. To ensure a sample 
size sufficient to provide an adequately powered study, a 
blinded review of the SD of the difference will occur at 
one-third and two-thirds of the way through recruitment.
statistical analysis
The first coprimary null hypothesis for the BEAMS study 
is that in people with COPD and chronic breathlessness, 
there is no difference in mean change from baseline to 
days 5-7 worst breathlessness intensity with the addition of 
regular, low-dose oral ER morphine when compared with 
placebo. The second coprimary null hypothesis is that in 
the same population, there is no difference in the mean 
change from baseline to days 5 to 7 in number of steps 
taken each day with the addition of regular, low-dose ER 
morphine when compared with placebo.
Appropriate statistical analysis will be performed to 
assess the validity of these null hypotheses on an intention 
to treat basis. Missing data will be imputed using multiple 
imputation with 50 resamples drawn.
The primary comparisons occur on the last 3 days of 
week 1; days 5 to 7 days post first randomisation. Primary 
comparisons are between:
 ► Placebo MP342 compared with 8 mg ER morphine 
daily;
 ► Placebo MP342 compared with 16 mg ER morphine 
daily.
To control the FWER for each coprimary endpoint at 
5%, each pairwise treatment comparison described 
above will be tested at the two-sided 2.5% significance 
level. The comparison will be deemed to be statistically 
significant if the associated p value is less than 0.025. To 
control the family-wise error rate at 5% across both copri-
mary endpoints, a hierarchical testing procedure will be 
used where the second coprimary endpoint for a partic-
ular pairwise treatment comparison will only be tested if 
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the first coprimary endpoint for that pairwise treatment 
comparison is statistically significant.
Change in worst breathlessness in the previous 24 hours 
between these groups will be evaluated using a linear 
random effects mixed-model adjusting for baseline score 
and using days 5–7 scores as outcomes, clustering over site 
and individual to account for correlated readings. The 
dependent variable is worst breathlessness in the previous 
24 hours, and the independent variables are group, day 
(and the interaction term of group and day), age, gender, 
baseline breathlessness, Charlson Comorbidity Index 
score, baseline end-tidal CO2, baseline oxygen saturation 
and AKPS. The effect of the interventions will be assessed 
as the difference between groups in mean change from 
baseline over days 5–7 at the end of week 1 (stage 1).
The difference in groups of who respond will also be 
explored using 2×2 tables of the proportion of people who 
achieve ≥1 point reduction in intensity of worse breath-
lessness in both primary comparison groups and tested 
using χ2. Baseline clinical and demographic predictors of 
response to opioids will also be explored in a secondary 
regression model to identify any participant subgroups 
who may be more likely to respond or indeed those who 
experience harm from study interventions. Standard 
sensitivity analyses will be undertaken with other prog-
nostic factors entered into the model. For all secondary 
endpoints where the two pairwise treatment comparisons 
are tested (placebo compared with 8 mg morphine; and 
placebo compared with 16 mg morphine), the FWER for 
that endpoint will be controlled at 5% by testing each 
pairwise treatment comparison at the two-sided 2.5% 
significance level. The comparison will be deemed to be 
statistically significant if the associated p-value is less than 
0.025.
Effects of any dose–response relationship will be 
assessed through comparison of the data obtained in 
stage 2 and 3 of the study of participants who achieve a 
≥1 point benefit at primary endpoint.
The FitBit Charge HR will provide data on step count 
and sleep-related information for each participant. Differ-
ences in absolute and percentage change (average of the 
changes at days 5, 6 and 7 of stage 1) for these data will be 
analysed. The second collection period during randomis-
ation 3 will be a secondary outcome.
Additional analysis will describe changes in worst 
breathlessness up to 14 days after last dose increment and 
any additional benefit in responders (>1 point improve-
ment) after subsequent blinded dose increment.
ethical considerations
As detailed previously, patient safety will remain of para-
mount importance throughout the study period. Adverse 
events and serious adverse events will be reported using 
a secure online reporting system to enable study wide 
reporting and reviewed by an independent contracted 
Data Safety Monitoring Committee. Serious adverse 
events will also be reported to the relevant human 
research ethics committee.
All study measures have been validated and selected 
to provide high-quality data while ensuring minimal 
physical stress to participants. The only invasive proce-
dure involved is blood testing which while potentially 
uncomfortable has been kept to an absolute minimum.
It is acknowledged that this is a potentially vulner-
able study population and discussion of sensitive issues 
related to functional status and quality of life may cause 
emotional or psychological stress. As such, the research 
team will always be attuned to monitoring for signs of 
participant distress and ongoing training will be provided 
to the research teams in conjunction with GCP princi-
ples.69 Carefully selected and trained staff will undertake 
all participant interactions.
Consent to participate in BEAMS and the relevant 
substudies will be obtained by a research team member 
not involved in the participant’s usual clinical care so that 
the potential participant is not in a dependant relation-
ship with the person discussing the study. This will also 
assist with the separation of research and clinical respon-
sibilities. All participants retain the ability to decline to 
participate in the study and participants can withdraw at 
any time without detriment to the provision or quality of 
their clinical care.
The protocol has been reviewed and approved by the 
Hunter New England Human Research Ethics Committee 
(HREC) (Reference No. 15/12/16/3.06) and New South 
Wales HREC (Reference No. HREC/15/HNE/502). 
Each individual collaborating site has also each obtained 
relevant Research Governance Office approvals to recruit 
to this study.
confidentiality
Participants will be allocated a unique ID number at 
entry and investigators will only have access to data by 
ID number only for both monitoring and analysis. The 
master list linking participant personal information and 
ID number will be maintained in a password-protected 
hard drive. Records relating to the study will be retained 
for 15 years after study completion and then destroyed 
in accordance with PaCCSC standard operating proce-
dures consistent with current HREC requirements.
dissemination
The results of this trial will be submitted for publication 
in relevant peer-reviewed publications and the key find-
ings presented at national and international conferences. 
If the study shows a net benefit, contact will also be made 
with key professional groups and regulatory and funding 
bodies. Negative findings will also be reported.
dIscussIon
This study protocol describes a large, multisite randomised 
study to further increase the evidence base for the use 
of ER morphine for chronic breathlessness in patients 
with COPD. There is a continued need for adequately 
powered, high-quality studies investigating this important 
area of symptom control. Equally, there is a need to ensure 
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adequate clinical evidence of benefit and minimal harms 
so physicians are reassured of the evidence-based safety of 
ER morphine for the symptom of chronic breathlessness, 
including benefits beyond 1 week.
The BEAMS study will answer several practical ques-
tions. First, it will address if regular, low-dose ER morphine 
at four possible once-daily doses over 3 weeks is more 
effective than placebo at improving breathlessness. It will 
therefore address the question of whether any beneficial 
clinical effect of ER morphine can be increased further 
by increased morphine dose. Through use of multiple 
assessments, BEAMS will allow determination of the 
effects on daily activity and quality of life while ensuring 
any potential serious side effects of ER morphine are 
documented and quantified. Regression analysis may also 
allow determination of participant subgroups that may 
be more likely to benefit from ER morphine for chronic 
breathlessness in COPD.
It is hypothesised that if the threshold for activity 
limited by breathlessness can be increased then, over 
time, mobility may also increase, even if the worst breath-
lessness experienced stays the same or even increases 
as people are able to tolerate activity better.105 Previous 
studies have shown that in patients with COPD, regular 
physical activity leads to both reduced COPD-related 
hospital admissions and mortality.106 107 The activity 
component to this study will therefore assess if ER 
morphine to manage chronic breathlessness may also 
improve activity.
BEAMS began recruitment in September 2016 and 
complete recruitment is anticipated within 2 years.
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